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Background: Real-world evidence of low-density lipoprotein cholesterol (LDL-C) goal attainment rates for Asian
patients is deficient. The objective of this study was to assess the status of dyslipidemia management, especially in
high-risk patients with cardiovascular disease (CVD) including stroke and acute coronary syndrome (ACS).
Methods: This was a retrospective cohort study of 514,866 subjects from the National Health Insurance Service-
National Health Screening Cohort database in Korea. Participants were followed up from 2002 to 2015. Subjects
with a high-risk of CVD prior to LDL-C measurement and subjects who were newly-diagnosed for high-risk of CVD
following LDL-C measurement were defined as known high-risk patients (n = 224,837) and newly defined high-risk
patients (n = 127,559), respectively. Data were analyzed by disease status: stroke, ACS, coronary heart disease (CHD),
peripheral artery disease (PAD), diabetes mellitus (DM) and atherosclerotic artery disease (AAD).
Results: Overall, less than 50% of patients in each disease category achieved LDL-C goals (LDL-C < 70 mg/dL in
patients with stroke, ACS, CHD and PAD; and LDL-C < 100 mg/dL in patients with DM and AAD). Statin use was
observed in relatively low proportions of subjects (21.5% [known high-risk], 34.4% [newly defined high-risk]). LDL-C
goal attainment from 2009 to 2015 steadily increased but the goal-achiever proportion of newly defined high-risk
patients with ACS remained reasonably constant (38.7% in 2009; 38.1% in 2015).
Conclusions: LDL-C goal attainment rates in high-risk patients with CVD and DM in Korea demonstrate unmet
medical needs. Proactive management is necessary to bridge the gap between the recommendations of clinical
guidelines and actual clinical practice.
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Cardiovascular disease (CVD) is the leading cause of
death globally, with 17.9 million estimated deaths from
CVD in 2016, representing 31% of all global deaths.
Myocardial infarction and stroke account for 85% of
CVD deaths [1]. Dyslipidemia is a major risk factor for
coronary heart disease (CHD) and stroke [2–5], and in-
cludes elevated total cholesterol, triglycerides, or low-
density lipoprotein cholesterol (LDL-C) levels, or low
high-density lipoprotein cholesterol (HDL-C) levels. The
global disease burden of CVD increased by 12.5% [6],
and this trend is attributed by Asians with fast growing
of aged population [7]. However, evidence is limited for
dyslipidemia management for high-risk CVD patients
among Asians. Recent data from the Korean National
Health and Nutrition Examination Survey (KNHANES)
reported that, in 2016, 19.9% of adults aged ≥30 years
had hypercholesteremia and 40.5% had dyslipidemia [8].
The prevalence of dyslipidemia in Korea has increased
in an age-dependent manner and is more evident in
women aged ≥50 years [8–11]. The level of disease
awareness was as low as 32.1% in men and 32.6% in
women (aged 30–49 years) [11]. In one recent study in
Korea, the prevalence of dyslipidemia was higher than
that of hypertension and diabetes mellitus (DM), but
dyslipidemia awareness and treatment rates were still
lower [12].
LDL-C remains the primary target of cholesterol-
lowering therapy for the primary and secondary preven-
tion of atherosclerotic cardiovascular disease (ASCVD)
events including CHD, stroke, and peripheral artery dis-
ease (PAD). The cardiovascular risk level of individuals
determines LDL-C treatment goals [2–4, 13–15]. Some
differences in cholesterol-lowering guidelines have been
described and these may, at least in part, be attributable
to whether the guidelines are solely evidence-based or
based on a combination of evidence and expert opinion
[16, 17]. On the other hand, management of dyslipid-
emia was revolutionized since statins were discovered.
Statins are known to substantially reduce LDL-C levels
and CVD mortality [18, 19]. Previous studies have
shown that further reductions in LDL-C levels by more
intensive statin therapy according to the risk of CVD
have further benefits [20, 21].
American College of Cardiology/American Heart As-
sociation (ACC/AHA) guidelines [3] emphasized > 50%
LDL-C reductions from baseline in high-risk patients.
European Society of Cardiology and European Athero-
sclerosis Society (ESC/EAS) guidelines in 2016 focused
on < 70 mg/dL LDL-C reductions in high-risk patients
[15]. Recently revised 2018 ACC/AHA guidelines
emphasize using an LDL-C threshold of 70 mg/dL for
considering the addition of non-statins to statin therapy
in very high-risk patients, including a history of multiplemajor ASCVD events or one major ASCVD event and
multiple high-risk conditions [22]. This means that, in
addition to percent LDL-C reductions from baseline, tar-
get LDL-C levels are also critical values as LDL-C treat-
ment goals for dyslipidemia management. The latest
Korean national guidelines were formulated from the
Committee of Clinical Practice of the Korean Society of
Lipid and Atherosclerosis for the Management of Dys-
lipidemia in 2018 [23]. It was generally based on the
third report of the National Cholesterol Education
Program-Adult Treatment Panel (NECP-ATP) [2] for
the risk stratification and LDL-C treatment goal. How-
ever, > 50% LDL-C reduction was recommended accord-
ing to ACC/AHA guidelines in case of ACS patients in
addition to the LDL-C target < 70 mg/dL and intensity
of statin also was recommend in accordance with the
ACC/AHA guidelines [3]. The target of the recent
American Association of Clinical Endocrinologists
guideline [4] for lowering LDL-C to less than 55 for ex-
treme high risk was not included in the recommenda-
tions yet as consensus from domestic experts will be
required.
Evidence of LDL-C goal attainment rates for Korean
patients compared with other recently updated guide-
lines is currently lacking, particularly in high-risk pa-
tients. Therefore, it is needed to evaluate the status of
dyslipidemia management in Korea in general, as well as
specifically addressing the status of high-risk patients
with stroke, acute coronary syndrome (ACS), CHD,
PAD, DM and atherosclerotic artery disease (AAD). This
study used absolute values for LDL-C level < 70mg/dL
in patients with very-high risk disease (stroke, ACS,
CHD and PAD) and < 100 mg/dL LDL-C in high-risk pa-
tients (DM and AAD); and > 50% reduction using re-
peated measured LDL-C levels, as LDL-C treatment
goals. Also, this study aimed to describe the time trends
of LDL-C goal attainment rate in recent years using ex-
tensive national data. To identify the most appropriate
populations to target with preventative therapies, sub-
group analyses were conducted.Methods
Study design
This retrospective cohort study used data from the Ko-
rean National Health Insurance Service-National Health
Screening Cohort (NHIS-HEALS), details of which have
been described elsewhere [24]. The NHIS has provided a
general national health screening program since 1995,
and a health screening program for transitional ages,
aimed at individuals aged 40 and 66 years, since 2007.
The general health screening program is applied at least
once every 2 years for the entire population of Korean
adults aged ≥40 years; the participation rate was 74.8% in
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health screening programs [25].
The NHIS-HEALS database comprised 514,866 sub-
jects (aged 40–79 years, 54.2% males) at baseline (2002–
2003) who were randomly selected by simple random
sampling using SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA) and represented 10% of all national health
screening participants (N = 5,148,695) in 2002 and 2003.
Participants were followed up from 2002 to 2015 and
data constructed in 2015. Variables included social and
economic qualifications, medical check-up results,
healthcare usage and survival status linked to national
death certificates [24]. The healthcare usage database in-
cluded information on records of inpatient and out-
patient usage (diagnosis, procedures, and prescriptions).
Diagnoses were coded according to the International
Classification of Disease, Tenth Revision (ICD-10) [26].Risk stratification
Korean national guidelines [23] based on the risk stratifi-
cation of NCEP-ATP III, categorized risk groups to very
high-risk, high-risk, moderate-risk and low-risk and rec-
ommended LDL-C treatment goals dependent on risk
assessment: very high-risk < 70 mg/dL, high-risk < 100
mg/dL, moderate-risk < 130 mg/dL, and low-risk < 160
mg/dL. Very high-risk consisted of ACS, stroke and
TIA, and PAD; high-risk consisted of carotid artery dis-
ease, abdominal aortic aneurysm, and DM. According to
guidelines, PAD and other AAD (including carotid ar-
tery disease and abdominal aortic aneurysm) were sepa-
rated to adjust different LDL-C target goal. ICD-10
codes and related procedures for risk stratification were
listed in Table 1.Table 1 Definition of high-risk disease by ICD-10 codes and
procedure code
Disease Diagnosis or procedure code
Stroke Diagnosis: I63a, I64a, I69.3b, G45, G46
ACS Diagnosis: I21a, I22a, I23
Procedure:
Coronary artery bypass graft: OA640–2, OA647–9, O1640–2,
O1647–9
Percutaneous coronary intervention: M6561–7, M6571–2
Percutaneous transluminal coronary angioplasty: M6551–4
CHD Diagnosis: I20.0, I20.9, I24.0, I25.1, I25.2b, I25.5, I25.6
PAD Diagnosis: I70.2, I73.1, I73.8, I73.9
DM Diagnosis: E10, E11, E12, E13, E14
AAD Diagnosis: I65.2, I71.3, I71.4, I71.5, I71.6
AAD atherosclerotic artery disease, ACS acute coronary syndrome, CHD
coronary heart disease, DM diabetes mellitus, ICD-10 International
Classification of Diseases (10th revision), PAD peripheral artery disease
aIncluded only in the case of hospitalization; bIncluded for Known high riskEligibility criteria
From the NHIS-HEALS database, patients with LDL-C
measurements during 2007–2013 were included. Al-
though data on participants’ total cholesterol levels are
available from 2002, data for triglyceride, HDL-C and
LDL-C levels are available for the health screening pro-
gram for transitional ages from 2007, and for general na-
tional health screening programs from 2009. Patients
with LDL-C measurement < 10mg/dL during 2007–
2013 were excluded. Subjects with a high-risk of CVD
including stroke, ACS, CHD, PAD, DM and AAD were
identified using ICD-10 codes and related procedures
(Table 1) and classified into two groups: 1) known high-
risk patients, 2) newly defined high-risk patients (Fig. 1).
Subjects previously identified as having a high-risk for
CVD, prior to measurement of LDL-C levels, were cate-
gorized as “known high-risk patients.” The index date is
the first LDL-C testing date during the study period.
Definition of high-risk status was required to be made in
the previous year including the index date. Subjects
categorized as “newly defined high-risk” were identi-
fied according to the following criteria: 1) patients
with more than two LDL-C measurements, and 2) pa-
tients who were newly diagnosed or underwent proce-
dures for high-risk CVD between two LDL-C
measurements. As LDL-C levels were available from
2007, patients with new cases of each disease could
be defined as having at least 5 years of disease-free
periods. For subjects with newly defined high-risk dis-
ease, the earliest date of visit regarding high-risk dis-
ease was defined as the index date. Here is an
example of the group definition. If a subject had five
LDL-C measurements during the follow up period
and there was a first diagnosis of DM prior to the
first LDL-C measurement, he or she was defined as a
known high-risk patient for DM; on the other hand,
there was a first ACS diagnosis between the third and
fourth LDL-C measurements, he or she was defined
as a newly diagnosed high-risk patient for ACS.
Outcome variables: LDL-C goal attainment
Target LDL-C levels were defined by the 2018 Korean
guidelines [23]. For patients with stroke, ACS, CHD
or PAD, defined as the very high-risk group, the tar-
get level was < 70 mg/dL. For patients with DM or
AAD, defined as high-risk group, the target level was
< 100 mg/dL. When patients with DM or AAD had
other concurrent high-risk diseases—stroke, ACS,
CHD or PAD—these patients were stratified into the
subgroups “DM with high-risk of CVD” and “AAD
with high-risk of CVD” for outcome analysis, because
their target level was < 70 mg/dL as very high-risk
group. To determine LDL-C target achievement, LDL-
C levels at the index date and LDL-C levels after the
Fig. 1 Flow chart of the selection of high-risk category subjects
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and newly defined high-risk patients, respectively.
LDL-C goal attainment by reduction rates were defined
by 2013 ACC/AHA guidelines: > 50% reduction in base-
line LDL-C for high-intensity statin and 30 to < 50% for
moderate-intensity statin; guidelines recommend high-
intensity statin therapy in patients with ASCVD or those
with DM aged > 45 years [3]. In the present study, the two
LDL-C levels just before and after the index date of newly
defined high-risk patients were used to calculate changes
in LDL-C levels. On average, the interval for the two LDL-
C tests was approximately 1 year, due to government pol-
icy for providing the health screening program.
Assessment of statin use
Statins included atorvastatin, fluvastatin, lovastatin, pita-
vastatin, pravastatin, rosuvastatin and simvastatin. Statin
therapy intensity was classified as high-intensity (atorva-
statin 40–80mg, rosuvastatin 20 mg), moderate-intensity
(atorvastatin 10–20 mg, fluvastatin 40–80mg, lovastatin
40 mg, pitavastatin 2–4 mg, pravastatin 40 mg, rosuvasta-
tin 5–10mg, simvastatin 20–40 mg), and low-intensity
(fluvastatin 20–40mg, lovastatin 20 mg, pitavastatin 1
mg, pravastatin 5–20mg, simvastatin 5–10 mg), accord-
ing to generic name and dose.
Statin exposure was assessed on or within 30 days be-
fore the index date using the prescription date and dur-
ation in known high-risk patients. For newly defined
high-risk patients, whether exposure to statin took place
from 30 days before to 90 days after the index date, using
prescription dates and duration was assessed. Subjects
were classified by their statin use history, as existing
users if receiving statins at the time of the index date or
within 6 months before the index date, or new users if
there was no record of statin use for 6 months prior to
the index date.Data analysis
General characteristics including age, sex, body mass
index (BMI), waist circumference, smoking, presence of
diabetes, presence of hypertension, systolic and diastolic
blood pressure measurements, fasting blood glucose
levels, total cholesterol, triglyceride, HDL-C and LDL-C,
are presented as mean and standard deviation (SD) for
continuous variables and as frequency and proportion
for categorical variables.
The proportion of patients attaining target LDL-C
levels was calculated by dividing the number of patients
with LDL-C level less than target level by the total num-
ber of patients. The proportion of patients with > 50%
reduction of LDL-C levels was calculated by dividing the
number of patients with > 50% reduction of LDL-C from
the previous LDL-C level by the total number of pa-
tients. All LDL-C measurements from the index date
were included to identify annual trend. Data were ana-
lyzed by disease status: stroke, ACS, CHD, PAD, DM
and AAD. Data were analyzed using SAS Enterprise
Guide 7.1 (SAS Institute, Cary, North Carolina, USA).
Results
Patients’ characteristics
The NHIS-HEALS database (n = 514,866) included high-
risk patients either before LDL-C measurement (known
high-risk; n = 224,837) or following LDL-C measurement
(newly defined high-risk; n = 127,559) (Fig. 1). Baseline
characteristics of subjects stratified by cardiovascular
risk category (known or newly defined high-risk), and by
disease, are shown in Tables 2 and 3. DM was the most
common disease in the known high-risk group (n = 153,
050), followed by PAD (n = 89,807), and CHD (n = 65,
868). In patients with newly defined high-risk for CVD,
PAD (n = 55,767) was the most common disease
followed by DM (n = 52,416), and CHD (n = 29,434)
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groups (62–66 years; known high-risk and newly defined
high-risk). For ACS (67.89%), CHD (52.82%), DM
(52.31%) and AAD (62.87%), more than half of all pa-
tients were men; for stroke (49.53%) and PAD (47.66%),
less than half of the patients were men.
Statin use
Relatively low proportions of subjects were under lipid-
lowering therapy with statin (21.5% [known high-risk],
34.4% [newly defined high-risk]). Among statin users, most
patients in both the known and newly defined high-risk
groups received moderate-intensity statin therapy (89.3–
92.5%). High-intensity statin therapy was least commonly
used in known high-risk patients, but more frequent in
newly defined high-risk patients: 2.8 and 12.5% (stroke), 6.1
and 32.0% (ACS), 2.7 and 8.3% (CHD), 1.8 and 3.0% (PAD),
2.0 and 4.4% (DM), and 3.3 and 10.4% (AAD), respectively.
Overall, 22.6 and 40.1% of known high-risk and newly de-
fined high-risk stroke patients, respectively, received statin
therapy (Fig. 2). For stroke patients defined as the known
high-risk group (n = 39,317), 1.5, 20.5 and 0.6% received
low-, moderate- or high-intensity statin therapy, respect-
ively. For stroke patients defined as the newly defined high-
risk (n = 17,410), corresponding values were 1.6, 33.5 and
5.0%. Overall, 49.4% of ACS patients with known high-risk
received statin therapy versus 78.0% of patients with newlyTable 2 Baseline characteristics in subjects stratified by cardiovascul
Stroke ACS
(n = 39,317) (n = 5309)
Mean age, years (±SD) 65.39 ± 9.43 65.09 ± 9.39
Male, n (%) 18,575 (47.24) 3442 (64.83)
Mean BMI, kg/m2 (±SD) 24.28 ± 3.16 24.35 ± 3.16
Mean waist circumference, cm (±SD) 83.5 ± 8.52 84.69 ± 8.37
Smoking, n (%)
non-smoker 27,731 (71.56) 3029 (58.07)
former smoker 6549 (16.90) 1370 (26.27)
current smoker 4474 (11.54) 817 (15.66)
DM, n (%) 23,175 (58.94) 3806 (71.69)
Hypertension, n (%) 30,727 (78.15) 4759 (89.64)
Mean systolic BP, mmHg (±SD) 128.08 ± 15.79 126.98 ± 16.2
Mean diastolic BP, mmHg (±SD) 78.06 ± 10.06 77.11 ± 10.24
Mean total cholesterol, mg/dL (±SD) 194.21 ± 40.18 177.03 ± 40.7
Mean triglycerides, mg/dL (±SD) 141.79 ± 83.48 139.2 ± 79.8
Mean HDL-C level, mg/dL (±SD) 53.6 ± 31.11 52.22 ± 36.79
Mean LDL-C level, mg/dL (±SD) 114.02 ± 38.97 99.71 ± 39.85
Mean fasting plasma glucose, mg/dL (±SD) 104.49 ± 29.4 108.7 ± 35.96
* Variables from the health screening program were included missing data. Missing
for systolic BP, 0.04 for diastolic BP, 0.001 for total cholesterol, 0.08 for triglycerides,
AAD atherosclerotic artery disease, ACS acute coronary syndrome, CHD coronary hedefined high-risk. In ACS patients with known high-risk
(n = 5309), 2.3, 44.1 and 3.0% received low-, moderate- or
high-intensity statin therapy, respectively; corresponding
values were 1.1, 52.0 and 24.9%, in ACS patients with newly
defined high-risk (n = 2479). This difference was largely due
to a higher proportion of newly defined high-risk patients
receiving high-intensity statin therapy compared with
known high-risk patients (24.9% vs. 3.0%) (Fig. 2).
Statins were also used more frequently in newly de-
fined high-risk patients compared with known high-risk
patients in CHD (40.8% vs. 27.3%), PAD (27.1% vs.
17.5%), DM (32.1% vs. 19.8%) and AAD (61.3% vs.
44.2%) (Fig. 2). In newly defined high-risk stroke patients
(n = 17,410), 23.1% were existing statin users and 17.0%
were new statin users. In newly defined high-risk ACS
patients (n = 2479), 31.7% were existing users, and 46.2%
were new users (Fig. 3).
LDL-C goal attainment rates
LDL-C goal attainment rates in all high-risk patients
(known plus newly defined), defined according to target
LDL-C level and stratified by disease, are shown in Fig. 4a.
LDL-C goal attainment rates in stroke patients (n = 56,
727) for < 70mg/dL were 11.7%; and in ACS patients (n =
7788) were 26.3%. In CHD patients (n = 95,302), LDL-C
attainment rates for < 70mg/dL were 12.7%; and, in PAD
patients (n = 145,574), were 9.2% (Fig. 4a).ar risk category and disease: known high-risk patients
CHD PAD DM AAD
(n = 65,868) (n = 89,807) (n = 153,050) (n = 2200)
63.41 ± 9.21 63.79 ± 9.39 62.63 ± 9.11 66.45 ± 9.02
34,431 (52.27) 38,262 (42.6) 80,104 (52.34) 1380 (62.73)
24.51 ± 3.08 24.33 ± 3.15 24.39 ± 3.11 24.05 ± 3.06
83.94 ± 8.42 83.06 ± 8.5 83.69 ± 8.43 84.19 ± 8.47
43,183 (66.65) 64,638 (72.92) 99,636 (66.21) 1291 (59.69)
12,980 (20.03) 12,987 (14.65) 27,958 (18.58) 533 (24.64)
8625 (13.31) 11,012 (12.42) 22,887 (15.21) 339 (15.67)
38,946 (59.13) 46,651 (51.95) 153,050 (100.0) 1477 (67.14)
52,413 (79.57) 61,991 (69.03) 102,151 (66.74) 1918 (87.18)
127.34 ± 15.54 127.71 ± 15.71 127.37 ± 15.5 128.45 ± 16.43
77.8 ± 9.99 78.1 ± 9.99 77.9 ± 9.91 77.51 ± 10.23
2 191.38 ± 39.68 198.2 ± 39.88 195.06 ± 39.69 183.39 ± 41.46
140.41 ± 83.85 141.98 ± 84.27 144.76 ± 88.7 134.63 ± 75.27
53.45 ± 28.84 54.2 ± 27.02 53.47 ± 27.19 51.48 ± 21.36
111.47 ± 39.52 116.79 ± 38.37 113.99 ± 38.62 106.1 ± 41.52
105.12 ± 29.52 104.62 ± 29.76 111.58 ± 35.65 106.7 ± 31.86
rates (%) are 0.08 for BMI, 0.10 for waist circumference, 1.55 for Smoking, 0.04
0.004 for HDL-C level, 0.000 for LDL-C, and 0.002 for fasting plasma glucose
art disease, DM diabetes mellitus, PAD peripheral artery disease
Table 3 Baseline characteristics in subjects stratified by cardiovascular risk category and disease: newly defined high-risk patients
Stroke ACS CHD PAD DM AAD
(n = 17,410) (n = 2479) (n = 29,434) (n = 55,767) (n = 52,416) (n = 4624)
Mean age, years (±SD) 65.22 ± 8.76 65.71 ± 8.8 63.61 ± 8.51 63.21 ± 8.41 61.92 ± 8.3 65.74 ± 8.18
Male, n (%) 8623 (49.53) 1683 (67.89) 15,547 (52.82) 26,576 (47.66) 27,417 (52.31) 2907 (62.87)
Mean BMI, kg/m2 (±SD) 24.2 ± 2.96 24.47 ± 3.01 24.42 ± 3 24.25 ± 2.95 24.41 ± 3 24.21 ± 2.81
Mean waist circumference, cm (±SD) 82.99 ± 8.31 84.94 ± 8 83.44 ± 8.28 82.73 ± 8.29 83.09 ± 8.33 83.72 ± 8.07
Smoking, n (%)
non-smoker 11,835 (68.66) 1294 (52.84) 19,085 (65.55) 38,415 (69.63) 33,675 (64.96) 2636 (57.57)
former smoker 3015 (17.49) 536 (21.89) 5679 (19.5) 9508 (17.23) 10,006 (19.3) 1133 (24.74)
current smoker 2387 (13.85) 619 (25.28) 4353 (14.95) 7249 (13.14) 8162 (15.74) 810 (17.69)
DM, n (%) 8393 (48.21) 1274 (51.39) 13,860 (47.09) 24,589 (44.09) 0 (0.00) 2650 (57.31)
Hypertension, n (%) 10,910 (62.67) 1708 (68.90) 18,210 (61.87) 32,098 (57.59) 26,890 (51.30) 3300 (71.37)
Mean systolic BP, mmHg (±SD) 127.83 ± 15.67 129.22 ± 15.25 127.53 ± 15.42 126.89 ± 15.48 127.13 ± 15.46 128.4 ± 15.15
Mean diastolic BP, mmHg (±SD) 78.18 ± 10.04 78.41 ± 9.85 78.26 ± 10.03 77.86 ± 9.96 78.48 ± 10.06 77.78 ± 9.84
Mean total cholesterol, mg/dL (±SD) 199.09 ± 39 202.64 ± 43.09 199.54 ± 38.93 199.22 ± 38.59 203.88 ± 39.46 195.52 ± 40.2
Mean triglycerides, mg/dL (±SD) 140.53 ± 82.41 153.91 ± 88.65 141.5 ± 84.77 138.95 ± 83.78 146.67 ± 91.49 139.7 ± 80.57
Mean HDL-C level, mg/dL (±SD) 53.49 ± 23.68 50.51 ± 18.84 53.69 ± 24.23 54.42 ± 24.76 54.15 ± 22.38 52.06 ± 16.44
Mean LDL-C level, mg/dL (±SD) 118.37 ± 37.42 121.51 ± 39.64 118.52 ± 37.17 117.99 ± 37 121.2 ± 37.28 115.85 ± 37.4
Mean fasting plasma glucose, mg/dL (±SD) 103.58 ± 28.42 107.9 ± 33.18 103.76 ± 27.51 103.15 ± 27.36 106.94 ± 30.32 106.46 ± 29.8
* Variables from the health screening program were included missing data. Missing rates (%) for variables are 0.01 for BMI, 0.03 for waist circumference, 0.72 for
Smoking, 0.02 for systolic BP, 0.02 for diastolic BP, 0.000 for total cholesterol, 0.09 for triglycerides, 0.002 for HDL-C level, 0.000 for LDL-C, and 0.001 for fasting
plasma glucose
AAD atherosclerotic artery disease, ACS acute coronary syndrome, CHD coronary heart disease, DM diabetes mellitus, PAD peripheral artery disease
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CVD (n = 105,800) were higher for achieving < 70mg/dL
goals than for DM patients without high risk (n = 99,
666) (12.2% vs. 8.3%, respectively). Attainment rates for
≥70 to < 100 mg/dL (27.1% vs. 24.3%) were comparable.
Similarly, a higher proportion of patients with AAD with
high-risk (n = 5415) achieved < 70mg/dL goals than pa-
tients without high risk (n = 1409) (20.9% vs. 11.8%). Re-
spective attainment rates for ≥70 to < 100 mg/dL were
32.4% versus 28.7% (Fig. 4a).
In newly defined high-risk patients, LDL-C goal attain-
ment was defined as an LDL-C reduction > 50%, accord-
ing to ACC/AHA guidelines [3] (Fig. 4b). These goals
were achieved in 34.5% of 6981 stroke patients, 57.8% of
1933 ACS patients, 35.5% of CHD patients (n = 12,021),
25.4% of PAD patients (n = 15,136), 31.4% of DM pa-
tients (n = 16,801), and by 35.1% of AAD patients (n =
2836) (Fig. 4b).
Time trends of LDL-C goal attainment in known and
newly defined high-risk patients in each disease group
are shown in Fig. 5. In stroke patients, there were similar
upward trends from 2009 to 2015 in both known (from
9.7 to 15.1%) and newly defined (from 8.9 to 16.3%)
high-risk patients. In contrast, in ACS patients, the pro-
portion of known high-risk patients achieving LDL-C
goals increased steadily from 2009 to 2015 (from 19.7 to
27.6%), whereas the proportion of newly defined high-risk patients remained reasonably constant (38.7% in
2009 and 38.1% in 2015).
In CHD and PAD patients, the time-trend curves for
known and newly defined high-risk patients were virtu-
ally superimposable. In CHD patients, LDL-C goal at-
tainment steadily increased from 2009 to 2015: from
11.4 to 16.6% in known, and 12.9 to 16.2% in newly de-
fined high-risk patients. In PAD patients, goal attain-
ment rates from 2009 to 2015 were 8.5 to 13.1% in
known, and 9.3 to 11.7% in newly defined high-risk pa-
tients (Fig. 5).
Time trends in DM patients with or without high-risk
showed that DM patients without high-risk consistently
had higher LDL-C goal attainment rates than DM pa-
tients with high-risk, irrespective of the known or recent
diagnosis of high-risk. Attainment rates in 2015 for DM
patients without high-risk were 41.0 and 35.9%, respect-
ively, for known and newly defined high-risk groups,
compared with rates of 18.1 and 14.3% for newly defined
high-risk groups in DM patients with high-risk (Fig. 5).
Attainment rates of atherosclerosis patients with high-
risk were generally similar in newly defined high-risk pa-
tients (16.1% in 2011, 25.4% in 2015) compared with
known high-risk patients (14.6% in 2011, 20.8% in 2015),
although the attainment rate tended to be higher in newly
defined high-risk than in known high-risk in 2009. How-
ever, in atherosclerosis without high-risk, attainment rates
Fig. 2 Statin use in cardiovascular high-risk groups: a. in known high-risk patients and b. in newly defined high-risk patients. AAD, atherosclerotic
artery disease; ACS, acute coronary syndrome; CHD, coronary heart disease; DM, diabetes mellitus; PAD, peripheral artery disease
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Fig. 3 Patients previously receiving statins (existing user) or newly prescribed statins (new user)
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in 2009, 48.7% in 2015) than in newly defined high-risk
patients (33.3% in 2009, 45.0% in 2015) (Fig. 5).
Discussion
This retrospective study using the Korean NHIS-HEALS
large number database addressed that dyslipidemia man-
agement in patients with high-risk for CVD needs to be
improved. Although ACS patients who were newly de-
fined high-risk group was the most controlled among the
groups (34.4%), the control of LDL-C levels is still not
good enough considering consequence CVD risks and its
disease burden. Based on the key findings from this study,
LDL-cholesterol level reduction treatment strategies and
“treat to-target” groups need to be clarified.
Statin use was highest in patients with ACS or AAD.
Overall, 49.4 and 78.0% of ACS patients with known and
newly defined high-risk received statins, respectively,
whereas respective figures for patients with AAD were
44.2 and 61.3%. A recent US study found that, although
around 90% of high-risk patients started treatment with
statin monotherapy, treatment initiation with high-
intensity statins was ≤10% [27]. In present study, most
patients received moderate-intensity statin therapy; in
general, < 10% of patients received high-intensity statin
therapy. The exception was ACS patients with newly de-
fined high-risk, of whom 24.9% received high-intensity
statin therapy.Guidelines for lipid management in ACS patients vary,
and target values, have changed in recent years. 2013
ACC/AHA and 2016 ACC Expert Consensus Guidelines
recommend high-intensity statin therapy, which lowers
LDL-C levels on average by approximately ≥50%, and
moderate-intensity statin therapy, which lowers LDL-C
on average by approximately 30 to < 50% for patients
aged > 75 years or who are not candidates for high-
intensity statin therapy [3, 28]. These guidelines are also
applicable to patients with stroke or other clinical
ASCVD events [3, 28]. Current 2018 Korean guidelines
recommend LDL-C treatment goals dependent on risk
assessment: very high-risk < 70 mg/dL, high-risk < 100
mg/dL, moderate-risk < 130 mg/dL, and low-risk < 160
mg/dL [23]. Using 2013 ACC/AHA guideline target
values [3], goal attainment rates were relatively high
compared to those using the 2018 Korean guidelines,
even in the newly defined high-risk patient group (data
not shown). For example, in ACS, LDL-C goal attain-
ment rate was 26.3% by target LDL-C level and 57.8% by
reduction rate. One possible explanation is that doctors
treating high-risk patients consider that LDL-C 100mg/
dL is a sufficiently low attainment level for dyslipidemia
treatment, although data derived from KNHANES
(2014–2016) show that 17.6% of adult Koreans (aged
≥30 years) had hyper-LDL cholesterolemia (LDL-C ≥
160 mg/dL) [8]. On the other hand, the higher attain-
ment rate by reduction rate than by target LDL-C level,
Fig. 4 LDL-C goal attainment rates in a. all high-risk (known + newly defined high-risk patients) by target LDL-C level and b. in newly defined
high-risk patients stratified by disease by reduction rate
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intensity statin, may be related to higher statin efficacy
in Asians compared to Caucasians [29–32]. Further
studies are warranted for more appropriate secondary
prevention in high-risk patients.
Time-trend (2009–2015) for LDL-C goal attainment
were similar for comparisons of known and newly defined
high-risk patients with stroke, CHD, PAD, AAD with add-
itional high-risk disease or DM with/without additionalhigh-risk disease. In ACS, newly defined high-risk patients
had consistently higher attainment rates from 2009 to
2015 compared to known high-risk patients. Although
reasons for differences were not assessed in this study,
they possibly reflect patient medication adherence issues
[33, 34], and/or suboptimal performance and poor percep-
tion of physicians regarding attainment rates [35], result-
ing in patients receiving inadequate dosages or titration of
lipid-lowering medication [36, 37]. On the other hand,
Fig. 5 (See legend on next page.)
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Fig. 5 Time trends of goal attainment in known and newly defined high-risk patients with a. stroke; b. ACS; c. CHD; d. PAD; e. DM with high risk
of cardiovascular disease (CVD); f. DM without high risk of CVD; g. AAD with high risk of CVD; h. AAD without high risk of CVD. P for trend of
known high-risk and newly defined high-risk, respectively. a. < .0001 and < .0001; b. <.0001 and 0.1081; c. <.0001 and < .0001; d. <.0001
and < .0001; e. <.0001 and < .0001; f. <.0001 and < .0001; g. 0.0027 and < .0001; h. 0.0226 and 0.0138
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newly defined ACS patients, the gap had been narrowing
due to no improvement in newly defined ACS patient. It
also reflects suboptimal perception of physicians [35] in
newly diagnosed cases, but, further consideration is
needed for causes of no improvement of goal attainment
in newly defined ACS patients, in contrast to the increase
in known ACS patients.
There have been clinical practice changes due to
changes in the guidelines such as ACC/AHA [3] and
ESC/EAS [15] since the NCEP-ATP III guideline [2]. It
was expected that the use of high-intensity statins and
the achievement of LDL-C targets in the groups of the
high-risk and very high-risk increased. Although the
time trends of LDL-C goal attainment had been gener-
ally increasing in all groups except newly defined ACS
patients, most patients did not achieve LDL-C targets.
Attainment rates were < 50% for patients in each disease
category, including the best LDL-C target attainment
shown in ACS patients. Even in a previous Korean study
of diabetic patients treated by specialists, the LDL-C goal
attainment in patients receiving lipid-lowering therapy
was low at 47.4% in 2010 [35]. Comparable results (for
2010) in this study showed LDL-C goal attainment rates
of approximately 12 and 32%, in DM patients with or
without additional high-risk disease, respectively. Low
rates of LDL-C goal attainment have also been described
consistently in other countries, including 58% of recent
ACS patients in the Netherlands [38], 28.8% of ACS sur-
vivors in Hong Kong and Taiwan [39], 30% of German
atherosclerotic CVD patients [40], 41% of patients with
DM at very-high cardiovascular risk receiving statins in
France [41] and 38% of DM patients with ischemic heart
disease in a tertiary hospital in China [42]. In contrast, a
higher attainment rate (68%) for Japan Atherosclerosis
Society guideline-recommended LDL-C targets [43] was
reported in high-risk patients for CVD in Japan [44].
This study has several strengths. The current study is
derived from a nationally-representative cohort of Ko-
rean individuals (NHIS-HEALS database, n = 514,866)
with a relatively low attrition rate [24], reflecting real-
world clinical circumstances. Because information on
drug use and bio-clinical laboratory results were in-
cluded in databases, the risk of recall bias was elimi-
nated. Considering the lack of data in Asian populations
for estimating LDL-C goal achievement, results of this
study provide information on possible LDL-C reduction
rates. In addition, the estimation of goal attainment rateby LDL-C level (< 70mg/dL, 70–100 mg/dL for target
goal) and by percent of LDL-C reduction, together in a
large national cohort, is valuable.
However, this study also has some limitations. The result
needed to be interpreted with consideration of followings;
Subjects were selected based on the availability of LDL-C
measurements, which may limit the generalizability of re-
sults to general population. Additionally, the age of partici-
pant limited between 40 and 70 years and it may not be
applicable to goal attainment of young adult participants,
or oldest-old participants. In addition, due to the nature of
the NHIS-HEALS database, disease diagnosis variables may
reflect healthcare usage which is sensitive to the fee-for-
service payment and reimbursement system in Korea, ra-
ther than being an accurate reflection of a patient’s specific
medical condition.
Conclusions
LDL-C goal attainment rates in Korean patients with
CVD or with a high-risk for CVD are still poor, with <
50% of patients achieving LDL-C targets. Proactive ac-
tion is needed to improve dyslipidemia management in
high-risk patients with CVD, including those with stroke
or ACS.
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